Lo Re Mattia, Pezzoli Marta, Cocci Andrea, Cadenar Anna, Minervini Andrea, Garcia Rojo Esther, Nzeyimana Innocent, Romero Otero Javier, Alonso Isa Manuel, Garcia Gomez Borja
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
Unit of Oncologic Minimally Invasive Urology and Andrology, University of Florence, Careggi Hospital, 50100, Florence, Italy.
Int J Impot Res. 2025 Sep 13. doi: 10.1038/s41443-025-01165-9.
Erectile dysfunction affects around 40% of men and is increasingly prevalent with age and comorbid conditions like cardiovascular disease and depression. Inflatable penile prostheses could be considered one of the definitive treatments for this condition. This systematic review aims to compare the safety and durability of AMS 700® (Boston Scientific), Coloplast Titan® (Coloplast), Rigicon Infla 10® (Rigicon), and Zephyr ZSI 475® (Zephyr) inflatable penile prostheses, focusing on infection rates, removals, and mechanical failures. A systematic review following PRISMA guidelines was conducted. The search identified studies on penile prostheses safety and patient satisfaction. Inclusion criteria were studies on adult males undergoing three-component penile prosthesis implantation for erectile dysfunction reporting data on removal rates, causes, and mechanical failures. Studies on implantation of two-component or malleable penile prosthesis were excluded. After the screening, 30 studies published between 1994 and 2023 were included. The median follow-up duration ranged from 12 to 206 months. Removal rates ranged from 0% to 52.9%, generally below 10%, with infection rates typically under 5%. AMS 700® devices had removal rates from 0.3% to 52.9%, while Coloplast Titan® devices ranged from 0% to 6.2%. Rigicon Infla 10® showed a low mechanical failure rate of 2-3% over short follow-up periods. Zephyr ZSI 475® had high initial mechanical failure rates (25.7%). Mechanical failures varied widely, with AMS® reporting rates from 0 to 37.3%, Coloplast Titan® from 0 to 9.1% but with median shorter follow-up durations. Most inflatable penile prostheses demonstrate good long-term tolerance and durability. While AMS 700® and Coloplast Titan® prostheses are well-established, the low mechanical failure rates of the Rigicon Infla 10®, although promising, need to be confirmed by further studies with a longer follow-up. Preliminary Zephyr® data are inconclusive but highlight the need for further evaluations. Rigorous long-term follow-up and comparative studies are essential to confirm these findings and guide clinical decision-making.
勃起功能障碍影响着约40%的男性,且随着年龄增长以及诸如心血管疾病和抑郁症等合并症的出现,其发病率日益升高。可膨胀阴茎假体可被视为治疗该病症的确定性疗法之一。本系统评价旨在比较美国波士顿科学公司的AMS 700®、康乐保公司的Coloplast Titan®、瑞吉康公司的Rigicon Infla 10®和西风公司的Zephyr ZSI 475®可膨胀阴茎假体的安全性和耐用性,重点关注感染率、取出率和机械故障。按照PRISMA指南进行了一项系统评价。检索确定了关于阴茎假体安全性和患者满意度的研究。纳入标准为针对因勃起功能障碍接受三件式阴茎假体植入的成年男性的研究,报告取出率、原因和机械故障的数据。排除关于两件式或可弯曲阴茎假体植入的研究。筛选后,纳入了1994年至2023年间发表的30项研究。中位随访时间为12至206个月。取出率在0%至52.9%之间,一般低于10%,感染率通常低于5%。AMS 700®装置的取出率为0.3%至52.9%,而Coloplast Titan®装置的取出率在0%至6.2%之间。在短期随访期间,Rigicon Infla 10®的机械故障率较低,为2%至3%。Zephyr ZSI 475®的初始机械故障率较高(25.7%)。机械故障差异很大,美国美敦力公司(AMS®)报告的故障率在0至37.3%之间,Coloplast Titan®在0至9.1%之间,但中位随访时间较短。大多数可膨胀阴茎假体显示出良好的长期耐受性和耐用性。虽然AMS 700®和Coloplast Titan®假体已得到广泛应用,但Rigicon Infla 10®较低的机械故障率虽然很有前景,但需要通过更长随访期的进一步研究来证实。西风公司(Zephyr®)的初步数据尚无定论,但突出了进一步评估的必要性。严格的长期随访和比较研究对于证实这些发现并指导临床决策至关重要。